Philips Ultrasound is moving forward in its R&D program for Color Velocity Imaging-Quantification(CVI-Q), the vendor's unique non-Doppler method for quantifyingblood volume flow. Ten papers will be presented on CVI and CVI-Qat this week's American
Philips Ultrasound is moving forward in its R&D program for Color Velocity Imaging-Quantification(CVI-Q), the vendor's unique non-Doppler method for quantifyingblood volume flow. Ten papers will be presented on CVI and CVI-Qat this week's American Institute of Ultrasound in Medicine meetingin San Francisco.
Philips spent years developing CVI and CVI-Q and began shippingCVI-Q with its P700 SE scanners in February of 1994. Philips discontinuedthe P700 platform last year, however, in favor of SonoDiagnost800, which it developed in collaboration with Hewlett-Packard(SCAN 12/14/94 and 7/27/94).
Philips made a strategic decision not to ship CVI-Q on theinitial versions of SD 800 in order to position the platform asa mid-range system, according to Joe Balogh, senior marketingmanager for North America. Philips plans to introduce CVI-Q asan upgrade package for SD 800 later this year, he said.
"We decided to introduce the 800 at a mid-range pricepoint," Balogh said. "With CVI and CVI-Q, it would havecome in at a higher price point. We felt we'd gain more exposureestablishing it at the mid-range level."
The papers to be presented at the AIUM meeting cover work donewith the P700, according to Balogh. The papers cover topics rangingfrom the use of CVI-Q to monitor shunts and predict the likelihoodof graft failure to measuring cranial and extremity perfusion.Several presentations indicate that CVI-Q may be superior to conventionalDoppler methods of measuring blood flow.
New Study Examines Short-Term Consistency of Large Language Models in Radiology
November 22nd 2024While GPT-4 demonstrated higher overall accuracy than other large language models in answering ACR Diagnostic in Training Exam multiple-choice questions, researchers noted an eight percent decrease in GPT-4’s accuracy rate from the first month to the third month of the study.
FDA Grants Expanded 510(k) Clearance for Xenoview 3T MRI Chest Coil in GE HealthCare MRI Platforms
November 21st 2024Utilized in conjunction with hyperpolarized Xenon-129 for the assessment of lung ventilation, the chest coil can now be employed in the Signa Premier and Discovery MR750 3T MRI systems.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.